What is the address of BELIEPHARMA?

The registered office of BELIEPHARMA is located at Kerkstraat 21a, 9870 Zulte.

Is BELIEPHARMA still active?

Yes. According to the CBE (30 October 2026) BELIEPHARMA is active, legal situation “Normale toestand”, started on 27 March 1996.

Is BELIEPHARMA registered on Peppol?

Yes, BELIEPHARMA is registered on the Peppol network with ID 0208:0457655502.

What is the enterprise number of BELIEPHARMA?

The enterprise number of BELIEPHARMA is BE0457655502.

When was BELIEPHARMA founded?

BELIEPHARMA was founded on 27 March 1996.

Who are the directors of BELIEPHARMA?

According to the 2025 annual accounts, the directors of BELIEPHARMA are: Mark De Belie, Els Van Laere, Libelco Health BV, Pauline De Belie.

Is BELIEPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 March 1996; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did BELIEPHARMA make in 2025?

BELIEPHARMA posted a profit after taxes of € 103,043 in financial year 2025.

What is the revenue of BELIEPHARMA?

As a small company, BELIEPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 230,890.

How many employees does BELIEPHARMA have?

According to the 2025 annual accounts, BELIEPHARMA has 0 full-time equivalents (FTE).

BELIEPHARMA (Private Limited) - Zulte - BE0457655502

Q: What does BELIEPHARMA do?

BELIEPHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 27 March 1996, 1 establishment.

Dossier BELIEPHARMA, printed on 30 October 2026 from databakkes.be/en/0457655502/beliepharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 64 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

BELIEPHARMA from Zulte, company number BE0457655502, closed financial year 2025 with a result of € 103,043 after tax. For that financial year BELIEPHARMA recorded a gross margin of € 230,890 and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 114,234 to € 103,043. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2026.

What it is worth Growing

€ 1.2 million

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 103,043

▼ 10% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 53,744

▲ 15% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 20,000 paid out

19 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 113,861

▼ 13% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 286,884

▼ 27% vs 2024

€ 74,476 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 47,555

▲ € 36,832 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,168

▼ 62% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 150,732 Gross margin 2022: € 150,732 First fiscal year in the series	€ 373,816 Gross margin 2023: € 373,816 ▲ 148% vs 2022 (€ 150,732) Favourable step	€ 219,533 Gross margin 2024: € 219,533 ▼ 41% vs 2023 (€ 373,816) Unfavourable step	€ 230,890 Gross margin 2025: € 230,890 ▲ 5% vs 2024 (€ 219,533) Favourable step	▲ 5%
Profit after taxes	€ 55,815 Profit after taxes 2022: € 55,815 First fiscal year in the series	€ 216,073 Profit after taxes 2023: € 216,073 ▲ 287% vs 2022 (€ 55,815) Favourable step	€ 114,234 Profit after taxes 2024: € 114,234 ▼ 47% vs 2023 (€ 216,073) Unfavourable step	€ 103,043 Profit after taxes 2025: € 103,043 ▼ 10% vs 2024 (€ 114,234) Unfavourable step	▼ 10%
Equity	€ 1,096,064 Equity 2022: € 1,096,064 First fiscal year in the series	€ 1,027,648 Equity 2023: € 1,027,648 ▼ 6% vs 2022 (€ 1,096,064) Unfavourable step	€ 1,111,882 Equity 2024: € 1,111,882 ▲ 8% vs 2023 (€ 1,027,648) Favourable step	€ 1,194,925 Equity 2025: € 1,194,925 ▲ 7% vs 2024 (€ 1,111,882) Favourable step	▲ 7%
Total debts	€ 616,488 Total debts 2022: € 616,488 First fiscal year in the series	€ 797,272 Total debts 2023: € 797,272 ▲ 29% vs 2022 (€ 616,488) Unfavourable step	€ 769,107 Total debts 2024: € 769,107 ▼ 4% vs 2023 (€ 797,272) Favourable step	€ 694,688 Total debts 2025: € 694,688 ▼ 10% vs 2024 (€ 769,107) Favourable step	▼ 10%
Cash	€ 135,627 Cash 2022: € 135,627 First fiscal year in the series	€ 137,201 Cash 2023: € 137,201 ▲ 1% vs 2022 (€ 135,627) Favourable step	€ 46,761 Cash 2024: € 46,761 ▼ 66% vs 2023 (€ 137,201) Unfavourable step	€ 53,744 Cash 2025: € 53,744 ▲ 15% vs 2024 (€ 46,761) Favourable step	▲ 15%
Land & buildings	€ 415,676 Land & buildings 2022: € 415,676 First fiscal year in the series	€ 394,446 Land & buildings 2023: € 394,446 ▼ 5% vs 2022 (€ 415,676) Unchanged	€ 555,858 Land & buildings 2024: € 555,858 ▲ 41% vs 2023 (€ 394,446) Unchanged	€ 516,084 Land & buildings 2025: € 516,084 ▼ 7% vs 2024 (€ 555,858) Unchanged	▼ 7%
Retained profit	€ 1,089,864 Retained profit 2022: € 1,089,864 First fiscal year in the series	€ 1,021,448 Retained profit 2023: € 1,021,448 ▼ 6% vs 2022 (€ 1,089,864) Unfavourable step	€ 1,105,682 Retained profit 2024: € 1,105,682 ▲ 8% vs 2023 (€ 1,021,448) Favourable step	€ 1,188,725 Retained profit 2025: € 1,188,725 ▲ 8% vs 2024 (€ 1,105,682) Favourable step	▲ 8%
Dividend	€ 159,644 Dividend 2022: € 159,644 First fiscal year in the series	€ 284,488 Dividend 2023: € 284,488 ▲ 78% vs 2022 (€ 159,644) Unchanged	€ 30,000 Dividend 2024: € 30,000 ▼ 89% vs 2023 (€ 284,488) Unchanged	€ 20,000 Dividend 2025: € 20,000 ▼ 33% vs 2024 (€ 30,000) Unchanged	▼ 33%
Bank debt	€ 470,235 Bank debt 2022: € 470,235 First fiscal year in the series	€ 385,068 Bank debt 2023: € 385,068 ▼ 18% vs 2022 (€ 470,235) Favourable step	€ 395,460 Bank debt 2024: € 395,460 ▲ 3% vs 2023 (€ 385,068) Unfavourable step	€ 286,884 Bank debt 2025: € 286,884 ▼ 27% vs 2024 (€ 395,460) Favourable step	▼ 27%
Balance sheet total	€ 1,712,552 Balance sheet total 2022: € 1,712,552 First fiscal year in the series	€ 1,824,920 Balance sheet total 2023: € 1,824,920 ▲ 7% vs 2022 (€ 1,712,552) Unchanged	€ 1,880,989 Balance sheet total 2024: € 1,880,989 ▲ 3% vs 2023 (€ 1,824,920) Unchanged	€ 1,889,613 Balance sheet total 2025: € 1,889,613 Unchanged (€ 1,880,989) Unchanged

Key figures of BELIEPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BELIEPHARMA?

What happened at BELIEPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 21, 2026 New annual accounts for financial year 2025: profit of € 103,043 (▼ 10% vs 2024). filed late Source: NBB ↗
2024 Pauline De Belie became a director. NBB
2023 Mark De Belie became a director. NBB
2023 Els Van Laere became a director. NBB
2023 Libelco Health BV became a director. NBB
May 21, 1996 New establishment in Zulte. KBO
Mar 27, 1996 Start of the company according to the CBE. KBO

In short

From € 55,815 profit in 2022 to € 103,043 profit in 2025.

Paid € 177,223 in corporate taxes since 2022.

Best year ever: 2023, with € 216,073 profit.

Paid out € 494,133 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Mark De Belie

Els Van Laere

Libelco Health BV

Pauline De Belie

BELIEPHARMA

Apotheek De Belie 100%

Apotheek ter Platen 100%

Behind BELIEPHARMA are Mark De Belie, Els Van Laere, Libelco Health BV and Pauline De Belie. It owns 100% of Apotheek De Belie and 100% of Apotheek ter Platen itself.

Directors

According to the 2025 annual accounts

Mark De Belie

Director

since 2023

Els Van Laere

Director

since 2023

Libelco Health BV

Director · represented by De Belie Jan

Also active at: APOTHEEK TER PLATEN

since 2023

Pauline De Belie

Director

Also active at: Apotheek De Belie

since 2024

Establishments

Establishment units

Physical locations of this company

Registered office

Kerkstraat 21a

9870 Zulte

2.076.620.639

Kerkstraat 21 A

9870 Zulte

Active since 21 May 1996

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

GROEP DE BELIE

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0457.655.502

VAT number

BE 0457.655.502

Registered office

Kerkstraat 21a, 9870 Zulte

Names & denominations

BELIEPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 March 1996

Peppol

Active · Active since 25 Jan 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

BELIEPHARMA

Warning lights

Financials

What happened to BELIEPHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions